Upadacitinib
- Generic Name
- Upadacitinib
- Brand Names
- Rinvoq
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19F3N6O
- CAS Number
- 1310726-60-3
- Unique Ingredient Identifier
- 4RA0KN46E0
- Background
Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, auto...
- Indication
Upadacitinib is indicated for the treatment of moderately to severely active rheumatoid arthritis or active psoriatic arthritis in adult patients who have had an inadequate response or intolerance to one or more disease-modifying anti-rheumatic drugs (DMARDs), such as TNF blockers. In Europe, upadacitinib may be used as monotherapy or in combination with met...
- Associated Conditions
- Ankylosing Spondylitis (AS), Moderately to Severely Active Rheumatoid Arthritis, Moderately to Severely Active Ulcerative Colitis, Severe Atopic Dermatitis, Active Ankylosing spondylitis, Active Non-radiographic Axial Spondyloarthritis, Active Psoriatic arthritis, Moderate, active Crohn´s Disease, Moderate, refractory Atopic dermatitis, Refractory, severe Atopic Dermatitis, Severe, active Crohn´s Disease
- Associated Therapies
- -
Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Ottawa Hospital Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT05153200
A Study to Assess Disease Activity in Adult Participants With Axial Spondyloarthritis Who Receive Upadacitinib in a Real-world Setting
- First Posted Date
- 2021-10-26
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 352
- Registration Number
- NCT05094128
- Locations
- 🇩🇪
Praxis. F. Bigdeli-Wilshusen /ID# 272904, Hanover, Niedersachsen, Germany
🇩🇪ACURA Rheumazentrum Baden-Bade /ID# 249751, Baden-baden, Baden-Wuerttemberg, Germany
🇩🇪Heilig, Heidelberg, DE /ID# 240492, Heidelberg, Baden-Wuerttemberg, Germany
COVID-19 VaccinE Response in Rheumatology Patients
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Jeffrey Curtis
- Target Recruit Count
- 1000
- Registration Number
- NCT05080218
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona, United States
🇺🇸University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 185
- Registration Number
- NCT04927975
- Locations
- 🇺🇸
Duplicate_UMass Chan Medical School /ID# 228066, Worcester, Massachusetts, United States
🇺🇸Duplicate_Michigan Center for Research Company /ID# 228054, Clarkston, Michigan, United States
🇺🇸Oregon Medical Research Center /ID# 228073, Portland, Oregon, United States
A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil
- Conditions
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- AbbVie
- Registration Number
- NCT04666675
A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State
- Conditions
- Interventions
- First Posted Date
- 2020-06-30
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 185
- Registration Number
- NCT04451772
- Locations
- 🇺🇸
Deerbrook Medical Associates /ID# 227330, Libertyville, Illinois, United States
🇦🇷Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich /ID# 222569, Ciudad Autonoma Buenos Aires, Buenos Aires, Argentina
🇦🇷Instituto CAICI S.R.L /ID# 221892, Rosario, Santa Fe, Argentina
A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms
- First Posted Date
- 2020-06-12
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 68
- Registration Number
- NCT04430855
- Locations
- 🇺🇸
Medical Dermatology Specialist /ID# 221084, Phoenix, Arizona, United States
🇺🇸Beth Israel Deaconess Medical Center /ID# 218306, Boston, Massachusetts, United States
🇯🇵Takagi Dermatology Clinic /ID# 218587, Obihiro-shi, Hokkaido, Japan
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 485
- Registration Number
- NCT04195698
- Locations
- 🇺🇸
Dermatology Research Associates /ID# 218637, Los Angeles, California, United States
🇺🇸University of Arkansas for Medical Sciences /ID# 221021, Little Rock, Arkansas, United States
🇺🇸Clinical Science Institute /ID# 218632, Santa Monica, California, United States
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
- Conditions
- Interventions
- First Posted Date
- 2019-11-19
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 734
- Registration Number
- NCT04169373
- Locations
- 🇺🇸
Clinic of Robert Hozman/Clinical Investigation Specialists /ID# 215055, Skokie, Illinois, United States
🇺🇸Arthritis & Rheumatic Disease Specialties /ID# 215306, Aventura, Florida, United States
🇨🇦Toronto Western Hospital /ID# 215041, Toronto, Ontario, Canada
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
- Conditions
- Interventions
- First Posted Date
- 2019-11-13
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 56
- Registration Number
- NCT04161898
- Locations
- 🇧🇷
Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao /ID# 241175, Sao Paulo, Brazil
🇯🇵Institute of Science Tokyo Hospital /ID# 214138, Bunkyo-ku, Tokyo, Japan
🇰🇷The Catholic University of Korea, Seoul St. Marys Hospital /ID# 214566, Seoul, Seoul Teugbyeolsi, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.